Department of Hematology, Imperial College London, London, UK.
Biol Blood Marrow Transplant. 2011 May;17(5):632-9. doi: 10.1016/j.bbmt.2010.08.002. Epub 2010 Aug 11.
Limited data are available on immunologic responses to primary H1N1 infection in patients with hematologic malignancies. We present a prospective, case-surveillance study of such patients with real-time polymerase chain reaction (RT-PCR) confirmed H1N1-influenza who presented to our institution between September 2009 and January 2010. Ninety-two patients presented with influenza-like symptoms, and 13 had H1N1 infection confirmed by RT-PCR, including 4 allogeneic stem cell transplant recipients (1 with acute myelogenous leukemia, 1 with chronic lymphoblastic leukemia [CLL], 1 with non-Hodgkin lymphoma, and 1 with chronic myelogenous leukemia), 5 patients with multiple myeloma following autologous stem cell transplantation, 1 patient with multiple myeloma perimobilization, 2 patients with NHL post chemotherapy, and 1 patient with CLL. All 13 patients required hospitalization. Six (43%) were admitted to the intensive care unit (ICU), of whom 4 (67%) died. We evaluated B cell and T cell responses to H1N1 infection prospectively in these patients compared with those in 4 otherwise healthy controls. Within 12 weeks of diagnosis, only 6 of 11 patients developed seropositive antibody titers as measured by hemagglutination-inhibition or microneutralization assays, compared with 4 of 4 controls. H1N1-specific T cells were detected in only 2 of 8 evaluable patients compared with 4 of 4 controls. H1N1-specific T cells were functional, capable of producing interferon γ, tumor necrosis factor α, and CD107a mobilization. Furthermore, CD154 was up-regulated on CD4(+) T cells in 3 of 4 controls and 2 of 2 patients who had both B cell and T cell responses to H1N1. Post-H1N1 infection, 5 of 8 patients developed seasonal influenza-specific T cells, suggesting cross-reactivity induced by H1N1 infection. These data offer novel insights into humoral and cell-mediated immunologic responses to primary H1N1 infection.
有关血液恶性肿瘤患者初次感染 H1N1 后的免疫反应,相关数据有限。我们开展了一项前瞻性病例监测研究,对 2009 年 9 月至 2010 年 1 月期间我院确诊的经实时聚合酶链反应(RT-PCR)的 H1N1 流感患者进行了研究。92 例患者出现流感样症状,其中 13 例经 RT-PCR 证实存在 H1N1 感染,包括 4 例异基因造血干细胞移植受者(1 例急性髓系白血病、1 例慢性淋巴细胞白血病[CLL]、1 例非霍奇金淋巴瘤、1 例慢性髓系白血病)、5 例自体造血干细胞移植后多发性骨髓瘤患者、1 例多发性骨髓瘤围手术期患者、2 例化疗后非霍奇金淋巴瘤患者和 1 例 CLL 患者。所有 13 例患者均需住院治疗。6 例(43%)患者收入重症监护病房(ICU),其中 4 例(67%)死亡。我们前瞻性评估了这些患者与 4 例健康对照者感染 H1N1 后的 B 细胞和 T 细胞反应。在诊断后 12 周内,11 例患者中仅有 6 例(67%)经血凝抑制或微量中和测定血清抗体滴度呈阳性,而对照组 4 例均为阳性。8 例可评估患者中仅有 2 例检测到 H1N1 特异性 T 细胞,而对照组 4 例均为阳性。H1N1 特异性 T 细胞具有功能,能够产生干扰素 γ、肿瘤坏死因子 α 和 CD107a 动员。此外,4 例对照组中有 3 例和 2 例患者的 CD4(+)T 细胞上的 CD154 上调,这些患者对 H1N1 既有 B 细胞反应又有 T 细胞反应。感染 H1N1 后,8 例患者中有 5 例出现季节性流感特异性 T 细胞,提示 H1N1 感染诱导了交叉反应。这些数据为初次感染 H1N1 后的体液和细胞免疫反应提供了新的见解。